Skip to main content

Tahl Cindy's Form 4 filing

Fate Therapeutics Inc (FATE) · filed Jan 4, 2022

Accession no.
0001209191-22-000647
Filed
Jan 4, 2022
Trade date
Jan 3, 2022
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.97M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Tahl CindyCIK 0001655472Officer (General Counsel and Secretary)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 3, 2022Common StockMOption exerciseAcquired+50,000$6.55+$327,500219,006Direct
Jan 3, 2022Common StockSSaleDisposed−4,427$57.76F2−$255,703.52214,579Direct
Jan 3, 2022Common StockSSaleDisposed−16,900$58.84F3−$994,396197,679Direct
Jan 3, 2022Common StockSSaleDisposed−27,812$59.86F4−$1,664,826.32169,867Direct
Jan 3, 2022Common StockSSaleDisposed−861$60.31F5−$51,926.91169,006Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 3, 2022Common StockMOption exerciseDisposed−50,000$0.00$066,643Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents the weighted average sale price of the shares sold ranging from $57.26 to $58.18 to per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 5.

Referenced by the price of 1 transaction in Table I.

F3

Represents the weighted average sale price of the shares sold ranging from $58.26 to $59.25 per share.

Referenced by the price of 1 transaction in Table I.

F4

Represents the weighted average sale price of the shares sold ranging from $59.30 to $60.29 per share.

Referenced by the price of 1 transaction in Table I.

F5

Represents the weighted average sale price of the shares sold ranging from $60.30 to $60.33 per share.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)